Insider Selling: Cerus (NASDAQ:CERS) CFO Sells $99,007.44 in Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 33,676 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total transaction of $99,007.44. Following the completion of the transaction, the chief financial officer owned 1,062,188 shares in the company, valued at $3,122,832.72. This trade represents a 3.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cerus Stock Performance

CERS opened at $3.16 on Friday. Cerus Corporation has a twelve month low of $1.15 and a twelve month high of $3.21. The company has a quick ratio of 1.06, a current ratio of 1.63 and a debt-to-equity ratio of 0.47. The company has a fifty day moving average of $2.61 and a 200-day moving average of $2.30. The stock has a market cap of $633.17 million, a PE ratio of -63.20 and a beta of 1.77.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The business had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.18%. On average, sell-side analysts predict that Cerus Corporation will post -0.02 EPS for the current year.

Institutional Investors Weigh In On Cerus

A number of large investors have recently bought and sold shares of the stock. Globeflex Capital L P bought a new position in Cerus in the fourth quarter worth approximately $1,076,000. UBS Group AG increased its holdings in shares of Cerus by 227.1% during the fourth quarter. UBS Group AG now owns 1,142,502 shares of the biotechnology company’s stock valued at $2,354,000 after acquiring an additional 793,244 shares in the last quarter. Round Rock Advisors LLC acquired a new position in shares of Cerus during the fourth quarter worth approximately $545,000. CWM LLC raised its position in shares of Cerus by 6.8% during the fourth quarter. CWM LLC now owns 129,084 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 8,178 shares during the period. Finally, Hsbc Holdings PLC raised its position in shares of Cerus by 100.3% during the fourth quarter. Hsbc Holdings PLC now owns 203,922 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 102,114 shares during the period. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on CERS shares. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. BTIG Research upgraded Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a report on Friday, May 1st. Finally, Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.